evekhm/cms_iom_500 huggingface dataset:
(Medicare Claims Processing Manual)
or stress (exercise and/or pharmacologic)  3/14/95 G0039 *Myocardial Perfusion Imaging (following stress echocardiogram 93350); single study, rest or stress (exercise and/or pharmacologic)  3/14/95 G0040 *Myocardial Perfusion Imaging (following stress echocardiogram, 93350); multiple studies, rest or stress (exercise and/or pharmacologic)  3/14/95 G0041 *Myocardial Perfusion Imaging (following stress nuclear ventriculogram 78481 or 78483); single study, rest or stress (exercise and/or pharmacologic)  3/14/95 G0042 *Myocardial Perfusion Imaging (following stress nuclear ventriculogram 78481 or 78483); multiple studies, rest or stress (exercise and/or pharmacologic)  3/14/95 G0043 *Myocardial Perfusion Imaging (following stress ECG, 93000); single study, rest or stress (exercise and/or pharmacologic)  3/14/95 G0044 *Myocardial perfusion (following stress ECG, 93000), multiple studies; rest or stress (exercise and/or pharmacologic)  3/14/95 G0045 *Myocardial perfusion (following stress ECG, 93015), single study; rest or stress (exercise and/or pharmacologic)  3/14/95 G0046 *Myocardial perfusion (following stress ECG, 93015); multiple studies, rest or stress (exercise and/or pharmacologic)  3/14/95 G0047 PET imaging regional or whole body; single pulmonary nodule  1/1/98 G0125 Conditions  Coverage Effective Date  ****HCPCS/CPT  Lung cancer, non- small cell (PET imaging whole body)  Diagnosis, Initial Staging, Restaging 7/1/01
(Medicare Claims Processing Manual)
G0210 G0211 G0212 Colorectal cancer (PET imaging whole body)  Diagnosis, Initial Staging, Restaging  7/1/01  G0213 G0214 G0215 Melanoma (PET imaging whole body)  Diagnosis, Initial Staging, Restaging 7/1/01  G0216 G0217 G0218 Melanoma for non -covered indications  7/1/01 #G0219 Lymphoma (PET imaging whole body)  Diagnosis, Initial Staging, Restaging 7/1/01 G0220 G0221 G0222 Head and neck cancer; excluding thyroid and CNS cancers (PET imaging whole body or regional)  Diagnosis, Initial Staging, Restaging 7/1/01 G0223 G0224 G0225 Esophageal cancer (PET imaging whole body)  Diagnosis, Initial Staging, Restaging 7/1/01  G0226 G0227 G0228 Metabolic brain imaging for pre -surgical evaluation of refractory seizures  7/1/01 G0229 Metabolic assessment for myocardial viability following inconclusive SPECT study  7/1/01 G0230 Recurrence of colorectal or colorectal metastatic cancer (PET whole body, gamma cameras only)  1/1/02 G0231 Staging and characterization of lymphoma ( PET whole body, gamma cameras only)  1/1/02 G0232 Conditions  Coverage Effective Date  ****HCPCS/CPT  Recurrence of melanoma or melanoma metastatic cancer ( PET whole body, gamma cameras only)  1/1/02 G0233 Regional or whole body, for solitary pulmonary nodule following CT, or for initial staging of non-small cell lung cancer (gamma cameras only)  1/1/02 G0234 Non-Covered Service  PET imaging, any site not otherwise specified  1/28/05 #G0235 Non-Covered Service  Initial diagnosis of breast cancer and/or surgical planning for breast cancer (e.g., initial staging of axillary lymph nodes), not covered (full- and partial -ring PET scanners only)  10/1/02 #G0252 Breast cancer, staging/restaging of local regional recurrence or distant metastases,
(Medicare Claims Processing Manual)
lymph nodes), not covered (full- and partial -ring PET scanners only)  10/1/02 #G0252 Breast cancer, staging/restaging of local regional recurrence or distant metastases, i.e., staging/restaging after or prior to course of treatment (full- and partial -ring PET scanners only)  10/1/02 G0253 Breast cancer, evaluation of responses to treatment, performed during course of treatment (full - and partial -ring PET scanners only)  10/1/02 G0254 Myocardial imaging, positron emission tomography (PET), metabolic evaluation)  10/1/02 78459 Restaging or previously treated thyroid cancer of follicular cell origin following negative I -131 whole body scan (f ull- and partial -ring PET scanner only)  10/1/03 G0296 Tracer Rubidium**82 (Supply of Radiopharmaceutical Diagnostic Imaging Agent)  (This is only billed through Outpatient Perspective Payment System, OPPS.) (A/B MACs (B) must use HCPCS Code A4641). 10/1/03 Q3000 ***Supply of Radiopharmaceutical Diagnostic Imaging Agent, Ammonia N -13***  01/1/04 A9526 Conditions  Coverage Effective Date  ****HCPCS/CPT  PET imaging, brain imaging for the differential diagnosis of Alzheimers disease with aberrant features vs. fronto- temporal dementia  09/15/04 Appropriate CPT Code from section 60.3.1 PET Cervical Cancer  Staging as adjunct to conventional imaging, other staging, diagnosis, restaging, monitoring  1/28/05 Appropriate CPT Code from section 60.3.1
(Medicare Claims Processing Manual)
*NOTE:   A/B MACs (B)  must report A4641 for the tracer Rubidium 82 when used with PET scan codes G0030 through G0047 for services performed on or before January 27, 2005  **NOTE:   Not FDG PET   ***NOTE:  For dates of service October 1, 2003, through December 31, 2003, use temporary code Q4078 for billing this radiopharmaceutical.   60.3.1 - Appropriate CPT Codes Effective for PET Scans for Services Performed on or After January 28, 2005  (Rev.10881; Issued: 08- 06-2021; Effective: 09- 07-2021; Implementation: 09- 07- 2021)   NOTE: All PET scan services require the use of a radiopharmaceutical diagnostic imaging agent (tracer). The applicable tracer code should be billed when billing for a PET scan service. See section 60.3.2 below for applicable tracer codes.
(Medicare Claims Processing Manual)
CPT Code  Description  78429 Myocardial imaging, positron emission tomography (PET), metabolic evaluation study, single study; with concurrently acquired computed tomography transmission scan 78430 Myocardial imaging, positron emission tomography (PET), perfusion study; single study, at rest or stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan  78431 Myocardial imaging, positron emission tomography (PET), perfusion study; multiple studies at rest and stress, with concurrently acquired computed tomography transmission scan  78432 Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study, dual radiotracer;  78433 Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study, dual radiotracer; with concurrently acquired computed tomography transmission scan  78434 Absolute quantitation of myocardial blood flow (AQMBF), positron emission tomography (PET), rest and pharmacologic stress  78459 Myocardial imaging, positron emission tomography (PET), metabolic evaluation 78491 Myocardial imaging, positron emission tomography (PET), perfusion, single study at rest or stress  78492 Myocardial imaging, positron emission tomography (PET), perfusion, multiple studies at rest and/or stress  78608 Brain imaging, positron emission tomography (PET); metabolic evaluation  78811 Tumor imaging, positron emission tomography (PET); limited area (eg, chest, head/neck)  78812 Tumor imaging, positron emission tomography (PET); skull base to mid- thigh 78813 Tumor imaging, positron emission tomography (PET); whole body     60.3.2 - Tracer Codes Required for Positron Emission Tomography ( PET ) Scans  (Rev.10881; Issued: 08- 06-2021; Effective: 09- 07-2021; Implementation: 09- 07- 2021)
(Medicare Claims Processing Manual)
An applicable tracer/radiopharmaceutical code, along with an applicable Current Procedural Technology (CPT) code, is necessary for claims processing of any Positron Emission Tomography (PET) scan services. While there are a number of PET tracers already bi llable for a diverse number of medical indications, there have been, and may be in the future, additional PET indications that might require a new PET tracer. Under those circumstances, the process to request/approve/implement a new code could be time- intensive. To help alleviate inordinate spans of time between when a national coverage determination is made, or when the Food and Drug Administration (FDA) approves a particular radiopharmaceutical for an oncologic indication already approved by the Centers for Medicare & Medicaid Services (CMS), and when it can be fully  implemented via valid claims processing, CMS has created two new PET radiopharmaceutical unclassified tracer codes that can be used temporarily. This time period would be pending the creation/approval/implementation of permanent CPT codes that would later specifically define their function by CMS in official instructions.  Effective with dates of service on or after January 1, 2018, the following Healthcare Common Procedure Coding System (HCPCS) codes shall be used ONLY AS NECESSARY FOR AN INTERIM PERIOD OF TIME under the circumstances explained here. Specifically, there are two circumstances that would warrant use of the  CPT Code  Description  78814  Tumor imaging, positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization; limited area (e.g., chest, head/neck)  78815  Tumor imaging, positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization; skull base to mid -thigh  78816  Tumor imaging, positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization; whole body
(Medicare Claims Processing Manual)
below codes: (1) After FDA approval of a PET oncologic indication, or, (2) after CMS approves coverage of a new PET indication, and ONLY if either of those situations requires the use of a dedicated PET radiopharmaceutical/tracer that is currently non - existent. Once permanent replacement codes are officially implemented by CMS, use of the temporary code for that particular indication will simultaneously be discontinued. NOTE: The following two codes were effective as of January 1, 2017, with the January 2017 quarterly HCPCS update.   A9597 -  Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified  A9598 -  Positron emission tomography radiopharmaceutical, diagnostic, for non- tumor identification, not otherwise classified
(Medicare Claims Processing Manual)
Effective for claims with dates of service on and after January 1, 2018, when PET tracer code A9597 or A9598 are present on a claim, that claim must also include:  -an appropriate PET HCPCS code, either  78429, 78430, 78431, 78432, 78433, 78434, 78459, 78491, 78492, 78608, 78811, 78812, 78813, 78814, 78815, or 78816, -if tumor -related, either the - PI or - PS modifier as appropriate,  -if clinical trial, registry, or study -related outside of NCD220.6.17, PET for Solid Tumors, clinical trial modifier Q0,  -if clinical trial, registry, or study -related, all claims require the 8 -digit clinical trial number, -if Part A OP and clinical trial, registry, or study -related outside of NCD220.6.17, PET for Solid Tumors, also include condition code 30 and ICD -10 diagnosis Z00.6. Effective for claims with dates of service on and after January 1, 2018, A/Medicare Administrative Contractors (MACs) shall line -item deny, and B/MACs shall line -item reject, PET claims for A9597 or A9598 that don't include the elements noted above as appropriate.  Contractors shall use the following messaging when line -item denying (Part A) or line - item rejecting (Part B) PET claims containing HCPCS A9597 or A9598:  Remittance Advice Remark Codes (RARC) N386  Claim Adjustment Reason Code (CARC) 50, 96, and/or 119. Group Code CO (Contractual Obligation) assigning financial liability to the provider (if a claim is received with a GZ modifier indicating no signed ABN is on file).  (The above new verbiage will supersede any existing verbiage in chapter 13, section 60.3.2.)   60.3.3 - Denial Messages for Noncovered PET Services  (Rev. 3650, Issued: 11- 10-16, Effective: 02 -10-17, Implementation: 02- 10-17)
(Medicare Claims Processing Manual)
60.3.3 - Denial Messages for Noncovered PET Services  (Rev. 3650, Issued: 11- 10-16, Effective: 02 -10-17, Implementation: 02- 10-17)  The A/B MAC denies claims for noncovered procedure code, such as 78609.  The contractor shall use the following remittance advice messages and associated codes when rejecting/denying claims under this policy.  This CARC/RARC combination is compliant with CAQH CORE Business Scenario Three.   Group Code: CO  CARC: 96  RARC: N386  MSN: 16.10  60.4 - PET Scans for Imaging of the Perfusion of the Heart Using Rubidium 82 (Rb 82) (Rev. 223, Issued: 07- 02-04) (Effective/Implementation: Not Applicable)  For dates of service on or after March 14, 1995, Medicare covers one PET scan for imaging of the perfusion of the heart using Rubidium 82 (Rb 82), provided that the following conditions are met:    The PET is done at a PET imaging center with a PET scanner that has been approved by the FDA;    The PET scan is a rest alone or rest with pharmacologic stress PET scan, used for noninvasive imaging of the perfusion of the heart for the diagnosis and management of patients with known or suspected coronary artery disease, using Rb 82; and   Either the PET scan is used in place of, but not in addition to, a single photon emission computed tomography (SPECT) or the PET scan is used following a SPECT that was found inconclusive.   60.5 - Expanded Coverage of PET Scan for Solitary Pulmonary Nodules (SPNs)  (Rev. 223, Issued: 07- 02-04) (Effective/Implementation: Not Applicable)  For dates of service on or after January 1, 1998, Medicare expanded PET scan coverage to include characterization of solitary pulmonary nodules (SPNs).  60.6 - Expanded Coverage of PET Scans Effective for Services on or after July 1, 1999 (Rev. 223, Issued: 07- 02-04) (Effective/Implementation: Not Applicable)
(Medicare Claims Processing Manual)
Effective for services performed on or after July 1, 1999, Medicare expanded coverage of PET scans to include the evaluation of recurrent colorectal cancer in patients with rising levels of carinoembryonic antigen (CEA), for the staging of lymphoma (both H odgkins and non- Hodgkins) when the PET scan substitutes for a gallium scan or lymphangiogram, and for the staging of recurrent melanoma prior to surgery, provided certain conditions are met. All three indications are covered only when using the radiopharma ceutical FDG - (2-[flourine -18]-fluoro- 2-deoxy- D-glucose), and are further predicated on the legal availability of FDG for use in such scans.   60.7 - Expanded Coverage of PET Scans Effective for Services on or After July 1, 2001 (Rev. 223, Issued: 07- 02-04) (Effective/Implementation: Not Applicable)  See the Medicare National Coverage Determinations Manual, section 220.6, for specific coverage criteria for PET Scans. Coverage is expanded for PET scans to include the following effective July 1, 2001:    Scans performed with dedicated full -ring scanners will be covered. Gamma camera systems with at least a 1 inch thick crystal are eligible for coverage in addition to those already approved by CMS (FDA approved);    The provider must maintain on file the doctors referral and documentation that the procedure involved:   o Only FDA approved drugs and devices and,  o Did not involve investigational drugs, or procedures using investigational drugs, as determined by the FDA;    The ordering physician is responsible for certifying the medical necessity of the study according to the conditions.  The physician must have documentation in the beneficiarys medical record to support the referral supplied to the PET scan provider.   The following is a brief summary of the expanded coverage as of July 1, 2001:    PET is covered for diagnosis, initial staging and restaging of non -small cell lung cancer (NSCLC).    Usage of PET for colorectal cancer has been expanded to include diagnosis, staging, and restaging.    Usage of PET for the initial staging, and restaging of both Hodgkins and non- Hodgkins disease.
(Medicare Claims Processing Manual)
 Usage of PET for the initial staging, and restaging of both Hodgkins and non- Hodgkins disease.    Usage of PET for the diagnosis, initial staging, and restaging of melanoma.  (PET Scans are NOT covered for the evaluation of regional nodes.)    Medicare covers PET for the diagnosis, initial staging, and restaging of esophageal cancer.    Usage of PET for Head and Neck Cancers. (PET scans for head and neck cancer is NOT covered for central nervous system or thyroid cancers.)    Usage of PET following an inconclusive single photon emission computed tomography (SPECT) only for myocardial viability.  In the event that a patient has received a SPECT and the physician finds the results to be inconclusive, only then may a PET scan be ordered utilizing the proper documentation.   Usage of PET for pre -surgical evaluation for patients with refractory seizures.  NOTE:   Effective January 1, 2002, the definitions of HCPCS Codes G0210 through G0230 have been updated to properly reflect the type of PET scanner used.   60.8 - Expanded Coverage of PET Scans for Breast Cancer Effective for Dates of Service on or After October 1, 2002  (Rev. 527, Issued: 04- 15-05, Effective: 01 -28-05, Implementation: 04- 18-05)  Effective for dates of service on or after October 1, 2002, Medicare will cover FDG PET as an adjunct to other imaging modalities for staging and restaging for locoregional, recurrence or metastasis of breast cancer.  Monitoring treatment of a locally advanced breast cancer tumor and metastatic breast cancer when a change in therapy is contemplated is also covered as an adjunct to other imaging modalities.  The baseline PET study for monitoring should be done under the code for staging or restaging.   Medicare continues to have a national non- coverage determination for initial diagnosis of breast cancer and initial staging of axillary lymph nodes.  Medicare coverage now includes PET as an adjunct to standard imaging modalities for staging patients with distant metastasis or restaging patients with locoregional recurrence or metastasis of breast cancer; as an adjunct to standard imaging modalities for monitoring for women with locally advanced and metastatic breast cancer when a change in therapy is conte mplated.
(Medicare Claims Processing Manual)
CPT Codes for PET Scans Performed on or After October 1, 2002 for Breast Cancer   Contractors shall advise providers to use the appropriate CPT code from section 60.3.1 for covered breast cancer indications for services performed on or after January 28, 2005.  NOTE:  The NCD Manual contains a description of coverage.  FDG Positron Emission Tomography is a minimally invasive diagnostic procedure using positron camera [tomograph] to measure the decay of radioisotopes such as FDG.  The CMS determined that the benefit cate gory for the requested indications fell under 1861(s)(3)  of the Act diagnostic service.  60.9 - Coverage of PET Scans for Myocardial Viability  (Rev.10881; Issued: 08- 06-2021; Effective: 09- 07-2021; Implementation: 09- 07- 2021)     FDG PET is covered for the determination of myocardial viability following an inconclusive single photon computed tomography test (SPECT) from July 1, 2001, through September 30, 2002. Only full ring scanners are covered as the scanning medium for this service from July 1, 2001, through December 31, 2001. However, as of January 1, 2002, full and partial ring scanners are covered for myocardial viability following an inconclusive SPECT.  Beginning October 1, 2002, Medicare will cover FDG PET for the determination of myocardial viability as a primary or initial diagnostic study prior to revascularization, and will continue to cover FDG PET when used as a follow -up to an inconclusive SPECT. However, if a patient received a FDG PET study with inconclusive results, a follow -up SPECT is not covered. FDA full and partial ring PET scanners are covered. In the event that a patient receives a SPECT with inconclusive results, a PET scan may be perfor med and covered by Medicare. However, a SPECT is not covered following a FDG PET with inconclusive results. See the Medicare National Coverage Determinations Manual, Section 220.6 for specific frequency limitations for Myocardial Viability following an inconclusive SPECT.  Documentation that these conditions are met should be maintained by the referring provider as part of the beneficiarys medical record.    HCPCS Code for PET Scan for Myocardial Viability
(Medicare Claims Processing Manual)
Documentation that these conditions are met should be maintained by the referring provider as part of the beneficiarys medical record.    HCPCS Code for PET Scan for Myocardial Viability    78429- Myocardial imaging, positron emission tomography (PET), metabolic evaluation study, single study; with concurrently acquired computed tomography transmission scan  78432- Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study, dual radiotracer;   78433- Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study, dual radiotracer; with concurrently acquired computed tomography transmission scan   78459 -  Myocardial imaging, positron emission tomography (PET), metabolic evaluation   60.10 - Coverage of PET Scans for PET Scan for Thyroid Cancer  (Rev. 527, Issued: 04- 15-05, Effective: 01 -28-05, Implementation: 04- 18-05)  For services furnished on or after October 1, 2003, Medicare covers the use of FDG PET for thyroid cancer only for restaging of recurrent or residual thyroid cancers of folliculark cell origin that have previously been treated by thyroidectomy and radioiodine ablation and have a serum thyroglobulin > 10ng/ml and negative I -131 whole body scan.  Contractors shall advise providers to use the appropriate CPT code from section 60.3.1 for thyroid cancer for services performed on or after January 28, 2005.   60.11 - Coverage of PET Scans for Perfusion of the Heart Using Ammonia N- 13 (Rev. 223, Issued: 07- 02-04) (Effective/Implementation: Not Applicable)  Effective for service performed on or after October 1, 2003, PET scans performed at rest or with pharmacological stress used for noninvasive imaging of the perfusion of the heart for the diagnosis and management of patients with known or suspected coronary artery disease using the FDA -approved radiopharmaceutical ammonia N -13 are covered, provided the following requirements are met.  60.12 - Coverage for PET Scans for Dementia and Neurodegenerative Diseases  (Rev. 12364; Issued: 11- 16-23; Effective: 10 -13-23; Implementation:12- 19-23)